In accordance
with 5 CFR 1320, the information collection is not approved at this
time. Prior to publication of the final rule, the agency should
provide to OMB a summary of all comments received on the proposed
information collection and identify any changes made in response to
these comments.
Inventory as of this Action
Requested
Previously Approved
11/30/2021
36 Months From Approved
11/30/2021
54,426,919
0
54,426,919
8,667,195
0
8,667,195
0
0
0
Part D plans and, to the extent
applicable, MA organizations will use the information discussed
below to comply with the eligibility and other requirements
associated with their participation in Part D. CMS will use this
information from plan sponsors and States to approve contract
applications, monitor compliance with contract requirements, make
proper payment to plans, and ensure that correct information is
disclosed to potential and current enrollees. The new information
collection will allow CMS to ensure sponsors have plans in place to
restore business operations following a disruption of regular
operations. Medicare beneficiaries will use the information
provided by the Part D sponsors to make decisions regarding Part D
enrollment as well as grievance and appeal requests. Under
CMS-4182-P (RIN 0938-AT08), CMS will make the Preclusion List
available to Part D sponsors. The Part D sponsors will perform
system programming to maintain the Preclusion List in order to
reject a pharmacy claim (or deny a beneficiary request for
reimbursement) for a Part D drug that is prescribed by an
individual on the Preclusion List. CMS will create and disseminate
model notices to the prescribers to notify them of their existence
on the Preclusion List, while the Part D sponsors will create and
disseminate model notices to the Medicare beneficiaries to notify
them that the pharmacy claim is being rejected or denied due to the
prescriber’s existence on the Preclusion List.
Statute at
Large: 18
Stat. 1860 Name of Statute: null
PL:
Pub.L. 108 - 173 101 Name of Law: Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 (MMA)
PL: Pub.L. 108 - 173 101 Name of Law:
Medicare Prescription Drug, Improvement, and Modernization Act of
2003 (MMA)
We propose to add burden based
on the rule’s (CMS 4180-P, RIN 0938 AT08) Part D Explanation of
Benefits Drug Pricing Provision. For this provision the burden
includes the time and effort needed to link alternative prices to
the EOB model. We assume a half day (4 hr) for a software
programmer for each contract (757) to link drug prices to the Part
D EOB model, for a one time burden of +3,028 hours (757 x 4).
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.
Form CMS-10141 Medicare Prescription Drug Benefit Program (Plans)
CMS-10141 - Supporting Statement A (version 3).docx
Medicare Prescription Drug Benefit Program (Benes)